196 related articles for article (PubMed ID: 27052503)
21. Ovarian reserve after treatment with alkylating agents during childhood.
Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
[TBL] [Abstract][Full Text] [Related]
22. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
23. Could hormonal and follicular rearrangements explain timely menopause in unilaterally oophorectomized women?
Grynberg M; Labrosse J; Bennani Smires B; Sifer C; Peigne M; Sonigo C
Hum Reprod; 2021 Jun; 36(7):1941-1947. PubMed ID: 34037751
[TBL] [Abstract][Full Text] [Related]
24. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
25. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve.
Uncu G; Kasapoglu I; Ozerkan K; Seyhan A; Oral Yilmaztepe A; Ata B
Hum Reprod; 2013 Aug; 28(8):2140-5. PubMed ID: 23624580
[TBL] [Abstract][Full Text] [Related]
26. Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients.
Moolhuijsen LME; Louwers YV; McLuskey A; Broer L; Uitterlinden AG; Verdiesen RMG; Sisk RK; Dunaif A; Laven JSE; Visser JA
Hum Reprod; 2022 Jun; 37(7):1544-1556. PubMed ID: 35451015
[TBL] [Abstract][Full Text] [Related]
27. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
[TBL] [Abstract][Full Text] [Related]
28. Anti-Mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro.
Rosario R; Stewart HL; Spears N; Telfer EE; Anderson RA
Hum Reprod; 2024 Feb; 39(2):382-392. PubMed ID: 38070496
[TBL] [Abstract][Full Text] [Related]
29. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
[TBL] [Abstract][Full Text] [Related]
30. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?
Sonigo C; Simon C; Boubaya M; Benoit A; Sifer C; Sermondade N; Grynberg M
Hum Reprod; 2016 Jul; 31(7):1493-500. PubMed ID: 27165625
[TBL] [Abstract][Full Text] [Related]
31. Added value of anti-Müllerian hormone in prediction of menopause: results from a large prospective cohort study.
Dólleman M; Verschuren WM; Eijkemans MJ; Broekmans FJ; van der Schouw YT
Hum Reprod; 2015 Aug; 30(8):1974-81. PubMed ID: 26082477
[TBL] [Abstract][Full Text] [Related]
32. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
[TBL] [Abstract][Full Text] [Related]
33. Circulating anti-Müllerian hormone levels in pre-menopausal women: novel genetic insights from a genome-wide association meta-analysis.
Pujol-Gualdo N; Karjalainen MK; Võsa U; Arffman RK; Mägi R; Ronkainen J; Laisk T; Piltonen TT
Hum Reprod; 2024 May; ():. PubMed ID: 38815977
[TBL] [Abstract][Full Text] [Related]
34. Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age.
Bentzen JG; Forman JL; Larsen EC; Pinborg A; Johannsen TH; Schmidt L; Friis-Hansen L; Nyboe Andersen A
Hum Reprod; 2013 Jan; 28(1):247-55. PubMed ID: 23136135
[TBL] [Abstract][Full Text] [Related]
35. Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer.
van Dorp W; van den Heuvel-Eibrink MM; de Vries AC; Pluijm SM; Visser JA; Pieters R; Laven JS
Hum Reprod; 2014 Feb; 29(2):337-42. PubMed ID: 24345579
[TBL] [Abstract][Full Text] [Related]
36. Genetic variation may modify ovarian reserve in female childhood cancer survivors.
van Dorp W; van den Heuvel-Eibrink MM; Stolk L; Pieters R; Uitterlinden AG; Visser JA; Laven JS
Hum Reprod; 2013 Apr; 28(4):1069-76. PubMed ID: 23360674
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
Wang S; Pei L; Hu T; Jia M; Wang S
Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
[TBL] [Abstract][Full Text] [Related]
38. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
39. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
Alebić MŠ; Stojanović N; Duhamel A; Dewailly D
Hum Reprod; 2015 Aug; 30(8):1927-33. PubMed ID: 26048913
[TBL] [Abstract][Full Text] [Related]
40. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial.
Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
